• 8891_Labor_Versameb_Forschung_Jun18_foto-eberle
  • 8857_Labor_Versameb_Forschung_Jun18_foto-eberle
  • 8754_Labor_Versameb_Forschung_Jun18_foto-eberle
  • 8720_Labor_Versameb_Forschung_II

Versameb – transforming mRNA therapies in regenerative medicine


Versameb is a Swiss biopharmaceutical company developing innovative local mRNA treatments in regenerative medicine and beyond.


Versameb has achieved preclinical proof of concept in different injury models by showing a significant acceleration of tissue regeneration after injuries.


Versameb has a novel proprietary technology platform for enhanced therapeutic benefit through local mRNA treatment.


December 2018 | Versameb Ltd raises CHF 5.3 million for the development of mRNA therapies in regenerative medicine